Evidence map›Paper›PMID 31582786›Full record

ArticleScientific reports2019

Type I toxin-dependent generation of superoxide affects the persister life cycle of Escherichia coli.

Daniel Edelmann, Bork A Berghoff

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. A rational approach to discovering new persister control agents.Antimicrobial agents and chemotherapy · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Heterogeneous Phenotypic Responses of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2023
    Article
  17. The Functionality of IbpA fromInternational journal of molecular sciences · 2023
    Article
  18. Article
  19. Mechanism of action ofFrontiers in microbiology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel EdelmannInstitute for Microbiology and Molecular Biology, Justus Liebig University Giessen, 35392, Giessen, Germany.
Bork A BerghoffInstitute for Microbiology and Molecular Biology, Justus Liebig University Giessen, 35392, Giessen, Germany. Bork.A.Berghoff@mikro.bio.uni-giessen.de.ORCID http://orcid.org/0000-0002-6299-419X
Justus-Liebig-Universität Gießen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induction of growth stasis by bacterial toxins from chromosomal toxin-antitoxin systems is suspected to favor formation of multidrug-tolerant cells, named persisters. Recurrent infections are often attributed to resuscitation and regrowth of persisters upon termination of antibiotic therapy. Several lines of evidence point to oxidative stress as a crucial factor during the persister life cycle. Here, we demonstrate that the membrane-depolarizing type I toxins TisB, DinQ, and HokB have the potential to provoke reactive oxygen species formation in Escherichia coli. More detailed work with TisB revealed that mainly superoxide is formed, leading to activation of the SoxRS regulon. Deletion of the genes encoding the cytoplasmic superoxide dismutases SodA and SodB caused both a decline in TisB-dependent persisters and a delay in persister recovery upon termination of antibiotic treatment. We hypothesize that expression of depolarizing toxins during the persister formation process inflicts an oxidative challenge. The ability to counteract oxidative stress might determine whether cells will survive and how much time they need to recover from dormancy.

Indexed as

Anti-Bacterial AgentsBacterial ToxinsCiprofloxacinDrug Resistance, BacterialEscherichia coli InfectionsEscherichia coli K12Escherichia coli ProteinsHumansMembrane ProteinsSuperoxidesAnti-Bacterial AgentsBacterial ToxinsCiprofloxacinDinQ protein, E coliEscherichia coli ProteinsHokB protein, E coliMembrane ProteinsSuperoxidesTisB toxin, E coli

Identifiers

PMID31582786
PMCPMC6776643
OpenAlexW2977342814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.